Physician profile
Edwin J Perry
NPI 1295260578
$1,797.13
in general payments reported to CMS, 2019-2025
16 companies · $888 in 2025
The $888 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $70.95 · 2023: $269 · 2024: $569 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $537.86 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $321.83 | 2024-2025 | |
| Glaxosmithkline, LLC. | $174.76 | 2023-2025 | Shingrix, Arexvy, Penmenvy |
| Abbvie INC. | $169.29 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.35 | 2024-2025 | Jardiance, Jascayd |
| Lilly USA, LLC | $103.72 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $74.07 | 2024-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.99 | 2024-2025 | Xifaxan, Relistor |
| Bayer Healthcare Pharmaceuticals INC. | $34.66 | 2025 | |
| Exact Sciences Corporation | $34.26 | 2025 | The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $33.74 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $29.52 | 2025 | Zoryve |
| Astellas Pharma US INC | $22.16 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $21.89 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $20.19 | 2025 | Vpriv |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.84 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.